GlassScriptPhysician profile
Brayden Irving
NPI 1902488992
$1,252.13
in general payments reported to CMS, 2019-2025
15 companies · $22.89 in 2025
The $22.89 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $517 · 2023: $476 · 2024: $236 · 2025: $22.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $734.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $240.68 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $159.66 | 2022 | |
| Alexion Pharmaceuticals, INC. | $143.48 | 2024 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $141.67 | 2023 | Cuvitru, Entyvio |
| Novo Nordisk INC | $136.66 | 2022-2025 | Rybelsus, Ozempic |
| E.R. Squibb & Sons, L.L.C. | $124.74 | 2023 | Eliquis |
| Organon LLC | $75.88 | 2022-2024 | Nexplanon |
| Astrazeneca Pharmaceuticals LP | $38.70 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $38.31 | 2022 | |
| Exact Sciences Corporation | $37.41 | 2024 | Cologuard Collection Kit |
| Ucb, INC. | $34.16 | 2024 | Bimzelx |
| Intercept Pharmaceuticals, INC. | $25.47 | 2023 | Ocaliva |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.64 | 2023 | Cyltezo |
| Medtronic, INC. | $17.12 | 2022 | |
| Braintree Laboratories, INC. | $13.55 | 2023 | Sutab |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brayden Irving listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.